Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC filing.According to a filing with the U.S. Securities and Exchange Commission dated November 5, 2025, Renaissance Group disclosed a new position in Halozyme Therapeutics. The fund purchased 478,735 shares during the third quarter, with a transaction value totaling $35,110,422. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool